Physician
Sagis, PLLC
Sagis, PLLC was paid $3.17M by Medicaid between Jan 2018 and Dec 2024, across 21 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 40% of everything it billed.
33Billing provider infoSAGIS, PLLC
HOUSTON, TX 77092
HOUSTON, TX 77092
33aNPI1548549066assigned 08/15/2011
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$3.17M
24GClaims77,656
24DCodes billed21
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Texas
Rank by total paid#2 of 97
Median peer was paid$24K
This provider vs. median135×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,286 | $15K | |
| 2019 | 3,616 | $56K | |
| 2020 | 7,634 | $273K | |
| 2021 | 16,193 | $752K | |
| 2022 | 17,415 | $875K | |
| 2023 | 18,088 | $716K | |
| 2024incomplete | 12,424 | $486K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 40% | 38,045 | 35,322 | $1.28M |
| 88312 | 24% | 9,608 | 8,951 | $767K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 15% | 4,471 | 4,104 | $474K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.3% | 6,894 | 6,094 | $136K |
| 88313 | 3.2% | 1,897 | 1,785 | $103K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.2% | 1,312 | 1,064 | $101K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.4% | 2,761 | 2,304 | $77K |
| 88304 | 2.0% | 2,624 | 2,502 | $63K | |
| 88311 | 1.7% | 5,426 | 5,085 | $55K | |
| 88342 | <1% | 770 | 696 | $29K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,052 | 1,005 | $26K |
| 87481 | <1% | 1,192 | 845 | $24K |
9 more codes
| 88307 | <1% | 492 | $21K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 195 | $5K |
| 87640 | <1% | 250 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 255 | $3K |
| 88341 | <1% | 31 | $3K | |
| 87653 | <1% | 82 | $1K | |
| 87641 | <1% | 83 | $1K | |
| 87500 | <1% | 83 | $1K | |
| 88302 | <1% | 133 | $341.84 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCANGELOSI, JOHN (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Houston Pathology Associates | Houston, TX | $96K |
| Sagis PLLC | Houston, TX | $9K |
| J S Wilkenfeld MD & Associates | Huntsville, TX | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.